01/07/2015 - 3:26pm

Pharmavite earlier this year launched a product that capitalizes on two current growth trends — immunity supplements and the gummy format. 

01/07/2015 - 3:25pm

NBTY earlier this year expanded its Osteo Bi-Flex franchise with a line of joint care supplements “plus” — as in joint care plus energy or joint care plus muscle support.

01/07/2015 - 3:25pm

Three supplement categories are really helping to drive the business today.

01/07/2015 - 3:25pm

With tens and possibly hundreds of billions of dollars in potential savings still snagged in a regulatory limbo, federal lawmakers and health industry stakeholders strongly urged the Food and Drug Administration last month to knock down the final barriers to review and approval of biosimilar drugs for marketing in the United States.

01/07/2015 - 3:25pm

The pharmaceutical industry is back. Fueled by the launch of expensive, new biotech medicines, rising prices for both branded and generic drugs and a recent slowdown in branded-drug patent expirations and generic competition, the U.S. pharmaceutical market is staging a remarkable resurgence.

12/11/2014 - 6:51pm

The holiday season is the battery category’s best friend. A shift in the consumer electronics industry to built-in rechargeable batteries and the growth of do-it-all smartphones that replace many battery-operated devices has left the category in a slump. 

12/11/2014 - 6:49pm

The introduction of Chattem’s Nasacort 24HR in February was the big deal this year in the allergy space.

12/11/2014 - 6:49pm

Australian Dream is one of those hot external analgesic products that has been growing by greater than 20% across all channels. Drug Store News had an opportunity to dig a little deeper regarding the Nature s Health Connection s Australian Dream product with David Biernbaum of David Biernbaum and Assoc., who represents the product.

12/11/2014 - 6:49pm

External analgesics is a category replete with growth brands with a base of $497.8 million across total U.S. multi-outlets, and more than 8.1% in growth for the 52 weeks ended Sept. 7, according to IRI data.